Background and Objective: Imatinib mesylate is the first effective therapy for advanced unresectable gastrointestinal stromal tumours (GIST). Adoption of this therapy in clinical practice is ...

Bezuclastinib and Sutent combination therapy demonstrated improved PFS in GIST patients, especially those previously treated with Gleevec. The combination therapy targets multiple KIT mutations, ...

Again. GEORGE DEMETRI: So when we started doing the work on what now is known as Gleevec, we decided to look at an unusual kind of cancer called Gastro Intestinal Stromal Tumor - GIST, for short.

With this in mind, topics include: surgery in metastatic GIST; neoadjuvant and adjuvant therapy with imatinib; role of mutational analysis; maintenance TKI therapy; and radiological assessments of ...

Owing to tumor size and mitotic index, the patient was considered at high risk of tumor relapse and thus was entered into a clinical trial to receive adjuvant imatinib treatment. 4 months after ...

IDRX-42 is currently in the phase 1/1b StrateGIST 1 trial in patients with KIT-mutant GIST who have failed prior treatment with Novartis Gleevec/Glivec (imatinib mesylate) and other approved ...

The proceeds were earmarked for the ongoing phase 1/1b StrateGIST 1 trial of the selective KIT inhibitor in patients with KIT-mutant GIST who have failed prior treatment with Novartis Gleevec ...